Anal Canal Cancer Clinical Trial
Official title:
Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates
Comparative retrospective study of two anal canal brachytherapy techniques aimed at boosting [low dose rate (LDR) and high dose rate (HDR)]
Efficacy of anal canal interstitial brachytherapy evaluated by local relapse rate, Tolerance of interstitial brachytherapy of the anal canal evaluated by the rate of chronic toxicities. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05060471 -
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00754078 -
A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy
|
Phase 2 | |
| Not yet recruiting |
NCT03731754 -
"Cross" Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection
|
N/A | |
| Recruiting |
NCT05374252 -
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
|
Phase 3 | |
| Recruiting |
NCT02185443 -
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT05040815 -
Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer
|
Phase 2 | |
| Recruiting |
NCT03403465 -
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
|
Phase 2 | |
| Active, not recruiting |
NCT03946358 -
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
|
Phase 2 | |
| Withdrawn |
NCT03942900 -
Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma
|